0I8F.L - DENTSPLY SIRONA Inc.
| Previous close | 37.48 |
| Open | 37.63 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 37.63 - 38.69 |
| 52-week range | 26.53 - 42.51 |
| Volume | |
| Avg. volume | 1,238 |
| Market cap | 92.457M |
| Beta (5Y monthly) | 0.92 |
| PE ratio (TTM) | 0.23 |
| EPS (TTM) | 1.68 |
| Earnings date | 02 Aug 2023 - 07 Aug 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
ZacksCooper Companies (COO) Q2 Earnings and Revenues Beat Estimates
Cooper Companies' (COO) second-quarter fiscal 2023 revenues reflect a solid segmental performance despite a year-over-year decline in earnings.
ZacksHere's Why Dentsply (XRAY) Is a Great 'Buy the Bottom' Stock Now
After losing some value lately, a hammer chart pattern has been formed for Dentsply (XRAY), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
ZacksHere's Why You Should Retain DENTSPLY SIRONA (XRAY) Stock
DENTSPLY SIRONA (XRAY) continues to gain traction from a robust product portfolio. However, macroeconomic factors like weakened global demand, rising costs and forex woes persist.
Simply Wall St.DENTSPLY SIRONA Inc.'s (NASDAQ:XRAY) Prospects Need A Boost To Lift Shares
DENTSPLY SIRONA Inc.'s ( NASDAQ:XRAY ) price-to-sales (or "P/S") ratio of 2x might make it look like a buy right now...
ZacksDown -7.13% in 4 Weeks, Here's Why You Should You Buy the Dip in Dentsply (XRAY)
The heavy selling pressure might have exhausted for Dentsply (XRAY) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
- Simply Wall St.
Is There Now An Opportunity In DENTSPLY SIRONA Inc. (NASDAQ:XRAY)?
DENTSPLY SIRONA Inc. ( NASDAQ:XRAY ), is not the largest company out there, but it led the NASDAQGS gainers with a...
ZacksDENTSPLY SIRONA (XRAY) Q1 Earnings & Revenues Beat Estimates
DENTSPLY SIRONA's (XRAY) Q1 earnings and revenues decline year over year, driven by the unfavorable foreign currency movement and soft demand across all geographical segments.
ZacksCompared to Estimates, Dentsply (XRAY) Q1 Earnings: A Look at Key Metrics
Although the revenue and EPS for Dentsply (XRAY) give a sense of how its business performed in the quarter ended March 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
ZacksWhat's in Store for DENTSPLY SIRONA (XRAY) in Q1 Earnings?
DENTSPLY SIRONA's (XRAY) first-quarter 2023 results are likely to reflect strong performance in the Technologies & Equipment business.
- Simply Wall St.
A Look At The Fair Value Of DENTSPLY SIRONA Inc. (NASDAQ:XRAY)
Key Insights DENTSPLY SIRONA's estimated fair value is US$45.20 based on 2 Stage Free Cash Flow to Equity DENTSPLY...
ZacksHere's Why You Should Retain DENTSPLY SIRONA (XRAY) Stock Now
DENTSPLY SIRONA (XRAY) continues to gain traction from a robust product portfolio. However, macroeconomic factors like weakened global demand, rising costs and forex woes persist.
- Simply Wall St.
DENTSPLY SIRONA Inc. (NASDAQ:XRAY) Will Pay A US$0.14 Dividend In Four Days
Regular readers will know that we love our dividends at Simply Wall St, which is why it's exciting to see DENTSPLY...
- Simply Wall St.
DENTSPLY SIRONA Full Year 2022 Earnings: Revenues Beat Expectations, EPS Lags
DENTSPLY SIRONA ( NASDAQ:XRAY ) Full Year 2022 Results Key Financial Results Revenue: US$3.92b (down 7.3% from FY...
ZacksDENTSPLY SIRONA (XRAY) Q4 Earnings & Revenues Beat Estimates
DENTSPLY SIRONA's (XRAY) Q4 earnings and revenues decline year over year due to unfavorable foreign currency movement and soft demand across all geographical segments.
ZacksWhat's in Store for DENTSPLY SIRONA (XRAY) in Q4 Earnings?
DENTSPLY SIRONA's (XRAY) fourth-quarter results are likely to reflect strong performance in the Technologies & Equipment business.
- Simply Wall St.
DENTSPLY SIRONA (NASDAQ:XRAY investor three-year losses grow to 33% as the stock sheds US$357m this past week
DENTSPLY SIRONA Inc. ( NASDAQ:XRAY ) shareholders should be happy to see the share price up 19% in the last quarter...
- Zacks
DENTSPLY SIRONA's (XRAY) Preliminary FY22 Sales Meet Estimates
DENTSPLY SIRONA's (XRAY) preliminary results meet market expectation. While certain product categories are driving growth, macro headwinds continue to hurt the top line.
ZacksWhy Is Dentsply (XRAY) Up 1% Since Last Earnings Report?
Dentsply (XRAY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
ZacksDENTSPLY SIRONA (XRAY) Q3 Earnings & Revenues Miss Estimates
Despite a year-over-year decline in both earnings and revenues, DENTSPLY SIRONA's (XRAY) third-quarter results benefit from the Technologies & Equipment business.
- Simply Wall St.
The Return Trends At DENTSPLY SIRONA (NASDAQ:XRAY) Look Promising
If you're looking for a multi-bagger, there's a few things to keep an eye out for. Firstly, we'll want to see a proven...
ZacksWhat's in Store for DENTSPLY SIRONA (XRAY) in Q3 Earnings?
DENTSPLY SIRONA's (XRAY) third-quarter results are likely to reflect strong performance in the Technologies & Equipment business.
ZacksDexCom and Papa John's International have been highlighted as Zacks Bull and Bear of the Day
DexCom and Papa John's International are part of the Zacks Bull and Bear of the Day article.
Zacks3 Stocks From the Growing Digital Orthodontic Space in Focus
The orthodontic treatment market has experienced substantial recovery, primarily owing to the easing of restrictions and mass opening up of the economy in 2022.
- Zacks
DENTSPLY SIRONA (XRAY) Falls After Nasdaq's Delinquency Notice
The Nasdaq exchange issues a notice to DENTSPLY SIRONA (XRAY) for filing delinquency from the exchange and for non-compliance with the Nasdaq Listing Rules. Shares fall.
ZacksDENTSPLY SIRONA (XRAY) Up on Strong Q2 Preliminary Results
DENTSPLY SIRONA's (XRAY) preliminary second-quarter 2022 results reflect the normalizing business, aided by product launches and pricing adjustments. Shares rise.